Higher prognostic value of soluble fibrin complexes than D-dimer and fibrin degradation product for disseminated intravascular coagulation in patients with liver cirrhosis

Blood Coagulation and Fibrinolysis

Volumn 24, Issue 2, 2013, Pages 150-156

  Kim, Seon Young ^a   Kim, Ji Eun ^a,b   Kim, Hyun Kyung ^a,b   Kim, Inho ^b   Yoon, Sung Soo ^b   Park, Seonyang ^b  

^a Seoul National University   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

disseminated intravascular coagulation; liver cirrhosis; soluble fibrin complexes

Indexed keywords

ANTITHROMBIN; D DIMER; FIBRIN; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN; PROTEIN C; SOLUBLE FIBRIN COMPLEX; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISSEMINATED INTRAVASCULAR CLOTTING; FEMALE; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTHROMBIN TIME; SCHOOL CHILD; SCORING SYSTEM; THROMBOCYTE COUNT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CHILD; DISSEMINATED INTRAVASCULAR COAGULATION; FIBRIN; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; LIVER CIRRHOSIS; MIDDLE AGED; PROGNOSIS; YOUNG ADULT;

EID: 84873410653     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32835aef6b     Document Type: Article

References (23)

1. Hamano A, Tanaka S, Takeda Y, Umeda M, Sakata Y. A novel monoclonal antibody to fibrin monomer and soluble fibrin for the detection of soluble fibrin in plasma. Clin Chim Acta 2002; 318:25-32
2. Cauchie P, Cauchie C, Boudjeltia KZ, Carlier E, Deschepper N, Govaerts D, et al. Diagnosis and prognosis of overt disseminated intravascular coagulation in a general hospital: Meaning of the ISTH score system, fibrin monomers, and lipoprotein-C-reactive protein complex formation. Am J Hematol 2006; 81:414-419
3. Wada H, Wakita Y, Nakase T, Shimura M, Hiyoyama K, Nagaya S, et al. Increased plasma-soluble fibrin monomer levels in patients with disseminated intravascular coagulation. Am J Hematol 1996; 51:255-260
4. Wada H, Sase T, Matsumoto T, Kushiya F, Sakakura M, Mori Y, et al. Increased soluble fibrin in plasma of patients with disseminated intravascular coagulation. Clin Appl Thromb Hemost 2003; 9:233-240
5. Ieko M, Nakabayashi T, Tarumi T, Naito S, Yoshida M, Kanazawa K, et al. Soluble fibrin monomer degradation products as a potentially useful marker for hypercoagulable states with accelerated fibrinolysis. Clin Chim Acta 2007; 386:38-45
6. Kubo T, Kitajima I, Makinodan A, Niratsuka S, Inoue S, Otsuka G, et al. Fibrin monomer could be a useful predictor of pulmonary embolism after total hip arthroplasty: Preliminary report. J Orthop Sci 2001; 6:119-122
7. Dempfle CE, Kaden JJ, Haase KK, Borggrefe M. Course of indicators of thrombin activity in the early phase of acute myocardial infarction: Effect of fibrinolytic therapy and acute percutaneous coronary angioplasty. Thromb Haemost 2003; 90:147-154
8. Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol 2009; 145:24-33
9. Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001; 86:1327-1330
10. Zhang D, Hao J, Yang N. Protein C and D-Dimer are related to portal vein thrombosis in patients with liver cirrhosis. J Gastroenterol Hepatol 2010; 25:116-121
11. Tripodi A, Chantarangkul V, Mannucci PM. Acquired coagulation disorders: Revisited using global coagulation/anticoagulation testing. Br J Haematol 2009; 147:77-82
12. Dempfle CE, Wurst M, Smolinski M, Lorenz S, Osika A, Olenik D, et al. Use of soluble fibrin antigen instead of D-Dimer as fibrin-related marker may enhance the prognostic power of the ISTH overt DIC score. Thromb Haemost 2004; 91:812-818
13. Toh CH, Hoots WK. The scoring system of the Scientific and Standardisation Committee on disseminated intravascular coagulation of the International Society on Thrombosis and Haemostasis: A 5-year overview. J Thromb Haemost 2007; 5:604-606
14. Wada H, Usui M, Sakuragawa N. Hemostatic abnormalities and liver diseases. Semin Thromb Hemost 2008; 34:772-778
15. Mammen EF. Coagulation defects in liver disease. Med Clin North Am 1994; 78:54554
16. Northup PG, Caldwell SH. New concepts of coagulation and bleeding in liver disease. Intern Emerg Med 2010; 5:3-6
17. Roberts LN, Patel RK, Arya R. Haemostasis and thrombosis in liver disease. Br J Haematol 2010; 148:507-521
18. Tripodi A, Primignani M, Mannucci PM. Abnormalities of hemostasis and bleeding in chronic liver disease: The paradigm is challenged. Intern Emerg Med 2010; 5:7-12
19. Dempfle CE. The use of soluble fibrin in evaluating the acute and chronic hypercoagulable state. Thromb Haemost 1999; 82:673-683
20. Scheefers-Borchel U, Muller-Berghaus G, Fuhge P, Eberle R, Heimburger N. Discrimination between fibrin and fibrinogen by a monoclonal antibody against a synthetic peptide. Proc Natl Acad Sci U S A 1985; 82:7091-7095
21. Suzuki A, Ebinuma H, Matsuo M, Miyazaki O, Yago H. The monoclonal antibody that recognizes an epitope in the C-Terminal region of the fibrinogen alpha-chain reacts with soluble fibrin and fibrin monomer generated by thrombin but not with those formed as plasmin degradation products. Thromb Res 2007; 121:377-385
22. Selmayr E, Mahn I, Muller-Berghaus G. Crosslinking of soluble fibrin and fibrinogen. Thromb Res 1985; 39:467-474
23. Rotker J, Preissner KT, Muller-Berghaus G. Soluble fibrin consists of fibrin oligomers of heterogeneous distribution. Eur J Biochem 1986; 155:583-588